CRANBURY, N.J. , Jan. 22, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), today announced that two oral presentations and seven posters highlighting its development programs for Lysosomal Storage Disorders will be included at the 14 th Annual WORLD Symposium™ 2018, to be held February
CRANBURY, N.J. and MADRID, Spain , Jan. 17, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, has commenced the commercial launch of the precision medicine Galafold in Spain following final pricing and
310+ People with Fabry Disease Treated with Reimbursed Galafold® at YE17 FY18 Galafold Revenue Guidance of $75M-$85M Regulatory Agreement on Comparability of 1,000L Scale Engineering Material for Pompe Additional Pompe Phase 1/2 Clinical Study Results to be Presented at WORLDSymposium™
CRANBURY, N.J. , Dec. 21, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that John F. Crowley , Chairman and Chief Executive Officer, will present a corporate overview at the 36 th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 9, 2018
CRANBURY, N.J. , Dec. 14, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) to request approval of the oral precision medicine migalastat HCl ("migalastat") for the treatment of patients 16 years and
260+ Fabry Patients on Reimbursed Galafold™ (Migalastat) and On Target to Reach 300 Patients by Year-End 2017 U.S. NDA Submission for Migalastat Planned in 4Q17 Pompe Retrospective and Prospective Data Collection Studies Initiated Additional Pompe Clinical Data to be Presented at WORLD Symposium™
CRANBURY, N.J. , Oct. 25, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on Wednesday, November 8, 2017 at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2017 .
Mean Six-Minute Walk Distance Improved in ERT-Naive Patients (+42 Meters at 6 Months, +75 Meters at 9 Months) and ERT-Switch Patients (+35 Meters at 6 Months, +37 Meters at 9 Months) Persistent & Durable Reductions in Key Disease Biomarkers Pulmonary Function Generally Improved or Remained